These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 29743410)

  • 1. Safety of Reversing Anticoagulation by Protamine Following Elective Transfemoral Percutaneous Coronary Intervention in the Drug-Eluting Stent Era.
    Yamamoto S; Sakakura K; Taniguchi Y; Yamamoto K; Wada H; Momomura SI; Fujita H
    Int Heart J; 2018 May; 59(3):482-488. PubMed ID: 29743410
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mid-term Clinical Outcomes of Immediate Protamine Use Following Elective Percutaneous Coronary Interventions.
    Kubota M; Sakakura K; Yamamoto K; Taniguchi Y; Tsukui T; Seguchi M; Wada H; Momomura SI; Fujita H
    Int Heart J; 2020 Sep; 61(5):865-871. PubMed ID: 32921667
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and efficacy of immediate heparin reversal with protamine after complex percutaneous coronary intervention.
    Choi JH; Chun KJ; Jung SM; Lee SY; Chon MK; Lee SH; Hwang KW; Kim JS; Park YH; Kim JH
    BMC Cardiovasc Disord; 2022 May; 22(1):207. PubMed ID: 35538419
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Administration of protamine after coronary stent deployment.
    Briguori C; Di Mario C; De Gregorio J; Sheiban I; Vaghetti M; Colombo A
    Am Heart J; 1999 Jul; 138(1 Pt 1):64-8. PubMed ID: 10385766
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Protamine use in transcarotid artery revascularization is associated with lower risk of bleeding complications without higher risk of thromboembolic events.
    Liang P; Motaganahalli RL; Malas MB; Wang GJ; Eldrup-Jorgensen J; Cronenwett JL; Nolan BW; Kashyap VS; Schermerhorn ML
    J Vasc Surg; 2020 Dec; 72(6):2079-2087. PubMed ID: 32273225
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immediate removal of femoral-sheath following protamine administration in patients undergoing intracoronary paclitaxel-eluting-stent implantation.
    Rossi ML; Zavalloni D; Scatturin M; Gasparini GL; Lisignoli V; Presbitero P
    Expert Opin Pharmacother; 2007 Sep; 8(13):2017-24. PubMed ID: 17714056
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and Efficacy of Protamine Administration for Prevention of Bleeding Complications in Patients Undergoing TAVR.
    Al-Kassou B; Kandt J; Lohde L; Shamekhi J; Sedaghat A; Tabata N; Weber M; Sugiura A; Fimmers R; Werner N; Grube E; Treede H; Nickenig G; Sinning JM
    JACC Cardiovasc Interv; 2020 Jun; 13(12):1471-1480. PubMed ID: 32553337
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of high or low protamine dosing on postoperative bleeding following heparin anticoagulation in cardiac surgery. A randomised clinical trial.
    Meesters MI; Veerhoek D; de Lange F; de Vries JW; de Jong JR; Romijn JW; Kelchtermans H; Huskens D; van der Steeg R; Thomas PW; Burtman DT; van Barneveld LJ; Vonk AB; Boer C
    Thromb Haemost; 2016 Aug; 116(2):251-61. PubMed ID: 27277211
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Protamine usage following implantation of drug-eluting stents: a word of caution.
    Cosgrave J; Qasim A; Latib A; Aranzulla TC; Colombo A
    Catheter Cardiovasc Interv; 2008 Jun; 71(7):913-4. PubMed ID: 18383161
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adoption of radial access and comparison of outcomes to femoral access in percutaneous coronary intervention: an updated report from the national cardiovascular data registry (2007-2012).
    Feldman DN; Swaminathan RV; Kaltenbach LA; Baklanov DV; Kim LK; Wong SC; Minutello RM; Messenger JC; Moussa I; Garratt KN; Piana RN; Hillegass WB; Cohen MG; Gilchrist IC; Rao SV
    Circulation; 2013 Jun; 127(23):2295-306. PubMed ID: 23753843
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of 3-year clinical outcomes after transradial versus transfemoral percutaneous coronary intervention.
    Natsuaki M; Morimoto T; Furukawa Y; Nakagawa Y; Kadota K; Iwabuchi M; Shizuta S; Shiomi H; Kimura T
    Cardiovasc Interv Ther; 2012 May; 27(2):84-92. PubMed ID: 22623001
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Duration of Triple Antithrombotic Therapy and Outcomes Among Patients Undergoing Percutaneous Coronary Intervention.
    Koskinas KC; Räber L; Zanchin T; Pilgrim T; Stortecky S; Hunziker L; Blöchlinger S; Billinger M; Gartwyl F; Moro C; Moschovitis A; Jüni P; Heg D; Windecker S
    JACC Cardiovasc Interv; 2016 Jul; 9(14):1473-83. PubMed ID: 27478115
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Heparin and protamine titration do not improve haemostasis in cardiac surgical patients.
    Shore-Lesserson L; Reich DL; DePerio M
    Can J Anaesth; 1998 Jan; 45(1):10-8. PubMed ID: 9466020
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effect of protamine dosing variation on bleeding and transfusion after heparinisation for cardiopulmonary bypass.
    Kunz SA; Miles LF; Ianno DJ; Mirowska-Allen KL; Matalanis G; Bellomo R; Seevanayagam S
    Perfusion; 2018 Sep; 33(6):445-452. PubMed ID: 29544405
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Procedure-related bleeding in elective percutaneous coronary interventions.
    Ndrepepa G; Stephan T; Fiedler KA; Guerra E; Kufner S; Kastrati A
    Eur J Clin Invest; 2015 Mar; 45(3):263-73. PubMed ID: 25645583
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Editor's Choice - Protamine Reduces Serious Bleeding Complications Associated with Carotid Endarterectomy in Asymptomatic Patients without Increasing the Risk of Stroke, Myocardial Infarction, or Death in a Large National Analysis.
    Stone DH; Giles KA; Kubilis P; Suckow BD; Goodney PP; Huber TS; Powell RJ; Cronenwett JL; Scali ST
    Eur J Vasc Endovasc Surg; 2020 Dec; 60(6):800-807. PubMed ID: 33127243
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Periprocedural use of tirofiban in elective percutaneous coronary intervention for long coronary lesions in stable patients with overlapping drug-eluting stents--the PETITION study: a prospective, randomized, multicenter study.
    Zhang Q; Wang XL; Liao ML; Hu J; Yang ZK; Ding FH; Zhang JS; Du R; Zhu TQ; Shen WF; Zhang RY
    Catheter Cardiovasc Interv; 2015 Mar; 85 Suppl 1():762-9. PubMed ID: 25630513
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Outcome of Percutaneous Coronary Intervention for Significant Atherosclerotic Lesions in Segment Proximal to Myocardial Bridge at Left Anterior Descending Coronary Artery.
    Hao Z; Xinwei J; Ahmed Z; Huanjun P; Zhanqi W; Yanfei W; Chunhong C; Chan Z; Liqiang F
    Int Heart J; 2018 May; 59(3):467-473. PubMed ID: 29681571
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Major femoral bleeding complications after percutaneous coronary intervention: incidence, predictors, and impact on long-term survival among 17,901 patients treated at the Mayo Clinic from 1994 to 2005.
    Doyle BJ; Ting HH; Bell MR; Lennon RJ; Mathew V; Singh M; Holmes DR; Rihal CS
    JACC Cardiovasc Interv; 2008 Apr; 1(2):202-9. PubMed ID: 19463301
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Transradial versus transfemoral intervention for the treatment of left main coronary bifurcations: results from the COBIS (COronary BIfurcation Stenting) II Registry.
    Chung S; Yang JH; Choi SH; Song YB; Hahn JY; Choi JH; Lee SH; Jang Y; Yoon JH; Tahk SJ; Seung KB; Gwon HC
    J Invasive Cardiol; 2015 Jan; 27(1):35-40. PubMed ID: 25589699
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.